Plus: FDA approves Padcev/Keytruda for 1L advanced urothelial cancer, obesity play Fractyl files for IPO and updates from Merck, Syndax, AC Immune, BMS
FDA’s approval of Merck’s Welireg belzutifan to treat von Hippel-Landau disease represents the first marketing authorization of a therapy the pharma obtained via its $1 billion-plus